CJ CGV set to rebound after positive 1Q earnings Overseas units show strong performances
Translated by Kim So-in 공개 2021-05-12 08:04:32
이 기사는 2021년 05월 12일 07:49 thebell 에 표출된 기사입니다.
South Korea’s leading cinema chain CJ CGV is trying to rebound after being hit hard by the pandemic last year.CJ CGV reported revenue of 172.5 billion won ($154 million) and an operating loss of 62.8 billion won in the first quarter on the consolidated basis, industry sources said on Monday. Revenue decreased by 29% year-on-year, but its operating loss decreased by 8.8 billion won, showing signs of recovery.
It is encouraging that its overseas business posted positive financial performance. Its Chinese unit recorded revenue of 90.8 billion won in the first quarter, more than a six-fold increase compared to the same period last year. It also swung to an operating profit of 2.3 billion won from 32.8 billion won in loss. The Vietnamese unit’s operating profit also jumped by 433% to 3.2 billion won.
Both Chinese and Vietnamese markets are where anxiety about the Covid-19 has somewhat eased. Local contents gained huge popularity in the two markets, driving the cinema chain’s rebound.
There are growing expectations for earnings improvement in the domestic market after the pandemic.
A slew of Hollywood blockbuster movies are set to be released. “F9: The Fast Saga” will be released next week, with “Black Widow,” “007 No Time To Die,” and “The Boss Baby 2,” waiting to be released in the second half.
CJ CGV is streamlining its business while improving efficiency in response to the prolonged pandemic. (Reporting by Mi-hyung Chung)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- DS이앤이, 스마트 팩토리 첫발… 증축 공사 준공
- 쌍용정보통신, 1분기 매출 679억·영업손실 31억 기록
- [HLB '리보세라닙' 미국 진출기]진양곤 회장 "할 도리 다 했다, 남은 건 하늘의 뜻"
- [HLB '리보세라닙' 미국 진출기]아바스틴 왕위 잇는 '간암 타깃' 올인, '병용'으로 길 열었다
- 젬백스링크, 포니에이아이로부터 300억 투자유치
- [HLB '리보세라닙' 미국 진출기]K-바이오 모두가 주목한다, 미국 FDA 허가 결정 'D-1'
- [우리투자증권의 부활]'격전지' IB 비즈니스, 우리은행이 '열쇠' 쥐고 있다
- 드림텍, 반도체 모듈 사업 진출…인도서 모듈 양산
- 티에스넥스젠, 뉴로소나 투자로 글로벌 뇌질환 시장 진출
- [Red & Blue]엑스페릭스 품 떠나는 엑스플러스, 신사업 기대감 퍼질까